AstraZeneca: launches new Covid study
(CercleFinance.com) - AstraZeneca's share price continued to rise in London on Tuesday following the announcement of the launch of a clinical study on an innovative treatment for Covid-19.
Shortly before 9 am in London, its share was up 1.1%, having already risen by over 2% on Monday following encouraging news about its coronavirus vaccine project.
The stock has now risen by over 11% YTD, with a market capitalisation of 113 billion pounds (about 125 billion euros).
This morning AstraZeneca announced that it has launched a Phase 1 clinical trial for AZD7442, a combination of two monoclonal antibodies that it has licensed since June.
The aim of the study - which is due to include 48 participants aged 18 to 55 years in the UK - is to evaluate the safety, tolerability and pharmaco-kinetic effects of this combination therapy, both in a preventive setting in people exposed to the virus and in a curative setting in those already infected.
Discovered by the Vanderbilt University Medical Center in Nashville, Tennessee, these two monoclonal antibodies (mAbs) can simulate the properties of natural antibodies, AstraZeneca said.
Note that this clinical trial is funded by the US Department of Defense and the US Department of Health and Human Services.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Shortly before 9 am in London, its share was up 1.1%, having already risen by over 2% on Monday following encouraging news about its coronavirus vaccine project.
The stock has now risen by over 11% YTD, with a market capitalisation of 113 billion pounds (about 125 billion euros).
This morning AstraZeneca announced that it has launched a Phase 1 clinical trial for AZD7442, a combination of two monoclonal antibodies that it has licensed since June.
The aim of the study - which is due to include 48 participants aged 18 to 55 years in the UK - is to evaluate the safety, tolerability and pharmaco-kinetic effects of this combination therapy, both in a preventive setting in people exposed to the virus and in a curative setting in those already infected.
Discovered by the Vanderbilt University Medical Center in Nashville, Tennessee, these two monoclonal antibodies (mAbs) can simulate the properties of natural antibodies, AstraZeneca said.
Note that this clinical trial is funded by the US Department of Defense and the US Department of Health and Human Services.
Copyright (c) 2020 CercleFinance.com. All rights reserved.